Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65768 | 0.95 | — | — | |
| SCHEMBL29217487 | 0.95 | ALDH1A1 (0.36) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL358694 | 0.95 | ALDH1A1 (0.36) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL6890483 | 0.95 | — | — | |
| SCHEMBL893232 | 0.95 | ALDH1A1 (0.36) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL22129579 | 0.95 | ALDH1A1 (0.36) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL893375 | 0.91 | ALDH1A1 (0.33) | ALDH1A1KMT2A | |
| SCHEMBL893554 | 0.91 | ALDH1A1 (0.33) | ALDH1A1KMT2A | |
| SCHEMBL3957944 | 0.91 | ALDH1A1 (0.33) | ALDH1A1KMT2A | |
| SCHEMBL18239998 | 0.91 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140912-A1 | ABIETANES AND METHODS OF MAKING AND USING THE SAME | NATIONAL INSTITUTES OF HEALTH | 2024-05-02 | — | — | US | disclosed |
| WO-2023192921-A2 | ABIETANES AND METHODS OF MAKING AND USING THE SAME | THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-05 | — | — | WO | disclosed |
| US-10626216-B2 | High glass transition temperature polycarbonates derived from adamantane epoxides | PROMERUS, LLC (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190127522-A1 | HIGH GLASS TRANSITION TEMPERATURE POLYCARBONATES DERIVED FROM ADAMANTANE EPOXIDES | PROMERUS, LLC (US) | 2019-05-02 | — | — | US | disclosed |
| US-10227433-B2 | Cycloalkylnorbornene monomers, polymers derived therefrom and their use in pervaporation | PROMERUS, LLC (US) | 2019-03-12 | — | — | US | disclosed |
| US-10143638-B2 | Method of treating skin with ingenol mebutate | LEO LABORATORIES LIMITED (IE) | 2018-12-04 | — | — | US | disclosed |
| US-9895334-B2 | Treatment of virally induced lesions | LEO LABORATORIES LIMITED (IE) | 2018-02-20 | — | — | US | disclosed |
| EP-2137193-B1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2017-08-09 | — | — | EP | disclosed |
| EP-2395993-B1 | SKIN TREATMENT | LEO LABORATORIES LTD (IE) | 2017-06-21 | — | — | EP | disclosed |
| US-9527957-B2 | High glass transition temperature photoimageable polycarbonate polymers with pendent polycyclic functional groups | PROMERUS, LLC (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2152261-A1 | TREATMENT OF VIRALLY INDUCED LESIONS | Peplin Research Pty Ltd. (AU) | 2010-02-17 | — | — | EP | disclosed |
| EP-2137193-A2 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | Sanofi-Aventis (FR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009110901-A1 | SUBSTITUTED DIHYDRO, TRIHYDRO AND TETRAHYDRO CYCLOALKYLOXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF AS ALLOSTERIC MODULATORS OF MGLUR | SANOFI-AVENTIS (FR) | 2009-09-11 | — | — | WO | disclosed |
| US-20090215884-A1 | METHOD FOR WOUND HEALING | PEPLIN RESEARCH PTY LTD. (AU) | 2009-08-27 | — | — | US | disclosed |
| WO-2008131491-A1 | TREATMENT OF VIRALLY INDUCED LESIONS | PEPLIN RESEARCH PTY LTD (AU) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008112483-A2 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | WO | disclosed |
| EP-1965818-A1 | METHODS FOR WOUND HEALING | Peplin Research Pty Ltd. (AU) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008054718-A2 | COMPOUNDS AND COMPOSITIONS CONTAINING SILICON AND/OR OTHER HETEROATOMS AND/OR METALS AND METHODS OF MAKING AND USING THEM | WAKE FOREST UNIVERSITY (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2007059584-A1 | METHODS FOR WOUND HEALING | PEPLIN RESEARCH PTY LTD (AU) | 2007-05-31 | — | — | WO | disclosed |
| WO-2004071454-A2 | SUBSTITUTED AZETIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10143638-B2 | Method of treating skin with ingenol mebutate | RARB, MC1R, RARA | ALDH1A1 1716/4885THRB 2235/4885MEN1 903/4885 |
| US-20240140912-A1 | ABIETANES AND METHODS OF MAKING AND USING THE SAME | SYMPK, TXK, HYPK | ALDH1A1 953/4885THRB 3824/4885MEN1 4715/4885 |
| US-10227433-B2 | Cycloalkylnorbornene monomers, polymers derived therefrom and their use in pervaporation | NOTUM, AGPS, WEE1 | ALDH1A1 3394/4885THRB 4232/4885MEN1 2615/4885 |
| US-20090215884-A1 | METHOD FOR WOUND HEALING | CCL11, SHARPIN, SHH | ALDH1A1 997/4885THRB 4567/4885MEN1 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.